Download PDF
CC BY-NC-ND 4.0 · Arq Neuropsiquiatr 2021; 79(08): 686-691
DOI: 10.1590/0004-282X-ANP-2020-0185
Article

Determinants of self-efficacy in patients with Parkinson’s disease

Determinantes de autoeficacia en pacientes con enfermedad de Parkinson
Ingrid Estrada-Bellmann 
1   Universidad Autónoma de Nuevo León, Hospital Universitario “Dr. José E. González”, Servicio de Neurología, Monterrey, Nuevo León, México.
,
Jesús Daniel Meléndez-Flores 
1   Universidad Autónoma de Nuevo León, Hospital Universitario “Dr. José E. González”, Servicio de Neurología, Monterrey, Nuevo León, México.
2   Universidad Autónoma de Nuevo León, Facultad de Medicina, Monterrey, Nuevo León, México.
,
Carlos Rodrigo Cámara-Lemarroy 
1   Universidad Autónoma de Nuevo León, Hospital Universitario “Dr. José E. González”, Servicio de Neurología, Monterrey, Nuevo León, México.
3   University of Calgary, Department of Clinical Neurosciences, Cumming School of Medicine, Calgary, Canada.
4   University of Calgary, Hotchkiss Brain Institute, Cumming School of Medicine, Calgary, Canada.
,
Sergio Andrés Castillo-Torres 
1   Universidad Autónoma de Nuevo León, Hospital Universitario “Dr. José E. González”, Servicio de Neurología, Monterrey, Nuevo León, México.
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

ABSTRACT

Background: Self-efficacy is the individual’s assessment of his or hers ability to complete a specific task successfully and has been closely related to self-management and quality of life in several diseases. Objective: To investigate self-efficacy in a population of Parkinson’s disease (PD) patients in Mexico and study the factors that are associated with this measure. Methods: We carried out a cross-sectional observational study involving patients with PD in an outpatient neurology clinic in Mexico, using the following instruments: Spanish version of the Chronic Disease Self-Efficacy Scale (CDSES), Quality of Life Questionnaire PDQ-8, Movement Disorders Society-Unified Parkinson's disease Rating Scale (MDS-UPDRS), Montreal Cognitive Assessment (MoCA), and Non-Motor Symptom Scale (NMSS). Clinical and demographic variables were also recorded. Results: We included 73 patients with a mean age of 65 years and most patients were male. Patients with lower CDSES scores (<7.75) had worse scores in MDS-UPDRS, NMSS, and PDQ-8 scales. CDSES scores were significantly correlated with MDS-UPDRS Part I (r=-0.497, p=<0.001), Part II (r= -0.271, p=0.020), Part III (r=-0.304, p=<0.001), PDQ-8 (r=-0.472, p=<0.001), and NMSS (r=-0.504, p=<0.001). Furthermore, when assessing the simultaneous effect of covariates associated with CDSES score, only Mood/Apathy domain of NMSS was significant (beta= -0.446, t= -3.807, p= 0.012). Conclusions: PD patients with lower self-efficacy scores had worse motor and non-motor symptomatology and quality of life. Mood/Apathy disorders were negatively associated with self-efficacy and contributed significantly to this measure.

RESUMEN

Antecedentes: La autoeficacia es la autoevaluación de un individuo sobre su capacidad para completar una tarea con éxito y se ha relacionado con automanejo y calidad de vida en otras enfermedades. Objetivo: Investigar la autoeficacia en una población de pacientes con enfermedad de Parkinson (EP) en México y estudiar factores asociados con esta medida. Métodos: Realizamos un estudio observacional transversal con pacientes con EP en una clínica de neurología en México. Se registraron datos demográficos y escalas que evalúan la función motora (MDS-UPDRS), no motora (NMSS) y cognitiva (MoCA), así como la calidad de vida (PDQ-8). Para valorar autoeficacia se utilizó la versión en español de la Escala de autoeficacia de enfermedades crónicas (CDSES). Resultados: Se incluyeron 73 pacientes, con una edad media de 65 años y la mayoría eran hombres. Pacientes con puntajes CDSES más bajos (<7.75) tuvieron peores puntajes en las escalas MDS-UPDRS, NMSS y PDQ-8. Las puntuaciones de CDSES se correlacionaron significativamente con la escala MDS-UPDRS Parte I (r=-0.497, p=<0.001), Parte II (r= -0.271, p=0.020), Parte III (r=-0.304, p=<0.001), PDQ-8 (r= -0.472, p=<0.001), y NMSS (r=-0.504, p=<0.001). Al evaluar el efecto simultáneo de covariables asociadas con la escala CDSES, solo el dominio estado de ánimo/apatía del NMSS resultó significativo (Beta = -0.449, t = -3.783, p = <0.001). Conclusiones: Los pacientes con menores puntajes de autoeficacia tienen peor calidad de vida y sintomatología motora y no motora. Los trastornos del estado de ánimo contribuyen negativamente a la autoeficacia.

Keywords:

Parkinson Disease - Self Efficacy - Quality of Life - Mood Disorders - Cognition

Palabras clave:

Enfermedad de Parkinson - Autoeficacia - Calidad de Vida - Trastornos del Humor - Cognición

Authors’ contributions:

IEB, CRCL: contributed to the conception and design of the work; IEB, JDMF, SACT: contributed to acquisition and analysis of data; IEB, SACT: contributed to drafting of manuscript; IEB, CRCL: contributed to revision for intellectually important content; IEB, JDMF, CRCL, SACT: review and approval of the final version of the work.




Publication History

Received: 30 April 2020

Accepted: 15 October 2020

Article published online:
01 June 2023

© 2021. Academia Brasileira de Neurologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • References

  • 1 Chaudhuri KR, Odin P, Antonini A, Martinez-Martin P. Parkinson's disease: the non- motor issues. Parkinsonism Relat Disord. 2011 Dec 1;17(10):717-23. https://doi.org/10.1016/j.parkreldis.2011.02.018
  • 2 Uitti RJ. Treatment of Parkinson's disease: focus on quality of life issues. Parkinsonism Relat Disord. 2012 Jan 1;18 Suppl 1:S34-6. https://doi.org/10.1016/S1353-8020(11)70013-X
  • 3 Martinez-Martin P. The importance of non-motor disturbances to quality of life in Parkinson's disease. J Neurol Sci. 2011 Nov 15;310(1-2):12-6. https://doi.org/10.1016/j.jns.2011.05.006
  • 4 Lee C-N, Kim M, Lee HM, Jang J-W, Lee S-M, Kwon DY, et al. The interrelationship between non-motor symptoms in Atypical Parkinsonism. J Neurol Sci. 2013 Apr 15;327(1-2):15-21. https://doi.org/10.1016/j.jns.2013.01.034
  • 5 Li H, Zhang M, Chen L, Zhang J, Pei Z, Hu A, et al. Nonmotor symptoms are independently associated with impaired health-related quality of life in Chinese patients with Parkinson's disease. Mov Disord. 2010 Dec 15;25(16):2740-6. https://doi.org/10.1002/mds.23368
  • 6 Bandura A. Self efficacy: the exercise of control. New York (NY): Freedman Press; 1997. 604p.
  • 7 Quinn C, Toms G, Anderson D, Clare L. A review of self-management interventions for people with Dementia and Mild Cognitive Impairment. J Appl Gerontol. 2016 Nov;35(11):1154-88. https://doi.org/10.1177/0733464814566852
  • 8 Eccles FJR, Simpson J. A review of the demographic, clinical and psychosocial correlates of perceived control in three chronic motor illnesses. Disabil Rehabil. 2011 Sep 23;33(13-14):1065-88. https://doi.org/10.3109/09638288.2010.525287
  • 9 Rosqvist K, Hagell P, Odin P, Ekström H, Iwarsson S, Nilsson MH. Factors associated with life satisfaction in Parkinson's disease. Acta Neurol Scand. 2017 Jul;136(1):64-71. https://doi.org/10.1111/ane.12695
  • 10 Maly MR, Costigan PA, Olney SJ. Determinants of self efficacy for physical tasks in people with knee osteoarthritis. Arthritis Rheum. 2006 Feb 15;55(1):94-101. https://doi.org/10.1002/art.21701
  • 11 Rahman A, Ambler G, Underwood MR, Shipley ME. Important determinants of self-efficacy in patients with musculoskeletal pain. J Rheumatol. 2004 Jun;31(6):1187-92.
  • 12 Kahraman BO, Savci S, Ozsoy I, Acar S, Ozpelit E, Sevinc C, et al. Determinants of self-efficacy in patients with pulmonary arterial hypertension: a pilot study. Eur Respir J. 2016 Nov 8;48 Suppl 60:PA4436. https://doi.org/10.1183/13993003.congress-2016.PA4436
  • 13 Martinez-Martin P, Rodriguez-Blazquez C, Abe K, Bhattacharyya KB, Bloem BR, Carod-Artal FJ, et al. International study on the psychometric attributes of the non-motor symptoms scale in Parkinson disease. Neurology. 2009 Nov 10;73(19):1584-91. https://doi.org/10.1212/WNL.0b013e3181c0d416
  • 14 Hoops S, Nazem S, Siderowf AD, Duda JE, Xie SX, Stern MB, et al. Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology. 2009 Nov 24;73(21):1738-45. https://doi.org/10.1212/WNL.0b013e3181c34b47
  • 15 Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N. The PDQ-8: development and validation of a short-form parkinson's disease questionnaire. Psychol Health. 1997;12(6):805-14. https://doi.org/10.1080/08870449708406741
  • 16 Martinez-Martin P, Rodriguez-Blazquez C, Alvarez-Sanchez M, Arakaki T, Bergareche-Yarza A, Chade A, et al. Expanded and independent validation of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS). J Neurol. 2013 Jan;260(1):228-36. https://doi.org/10.1007/s00415-012-6624-1
  • 17 Martinez-Martin P, Skorvanek M, Rojo-Abuin JM, Gregova Z, Stebbins GT, Goetz CG. Validation study of the hoehn and yahr scale included in the MDS-UPDRS. Mov Disord. 2018 Apr;33(4):651-2. https://doi.org/10.1002/mds.27242
  • 18 Lorig KR, Ritter PL, González VM. Hispanic chronic disease self-management: a randomized community-based outcome trial. Nurs Res. 2003 Nov-Dec;52(6):361-9. https://doi.org/10.1097/00006199-200311000-00003
  • 19 Hermanowicz N, Jones SA, Hauser RA. Impact of non-motor symptoms in Parkinson’s disease: a PMDAlliance survey. Neuropsychiatr Dis Treat. 2019 Aug 5;15:2205-12. https://doi.org/10.2147/NDT.S213917
  • 20 Berganzo K, Tijero B, González-Eizaguirre A, Somme J, Lezcano E, Gabilondo I, et al. Motor and non-motor symptoms of Parkinson's disease and their impact on quality of life and on different clinical subgroups. Neurologia. 2016 Nov-Dec;31(9):585-91. https://doi.org/10.1016/j.nrl.2014.10.010
  • 21 García DS, Fonticoba T de D, Castro ES, Borrué C, Mata M, Vila BS, et al. Non-motor symptoms burden, mood, and gait problems are the most significant factors contributing to a poor quality of life in non-demented Parkinson's disease patients: results from the COPPADIS study cohort. Parkinsonism Relat Disord. 2019 Sep;66:151-7. https://doi.org/10.1016/j.parkreldis.2019.07.031
  • 22 Braak H, Del Tredici K, Rüb U, de Vos RA, Steur ENHJ, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003 Mar-Apr;24(2):197-211. https://doi.org/10.1016/S0197-4580(02)00065-9
  • 23 Munhoz RP, Moro A, Silveira-Moriyama L, Teive HA. Non-motor signs in Parkinson’s disease: a review. Arq Neuropsiquiatr. 2015 May;73(5):454-62. https://doi.org/10.1590/0004-282X20150029
  • 24 Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. Nat Rev Neurosci. 2017 Jul;18(7):435-50. https://doi.org/10.1038/nrn.2017.62
  • 25 Tonga JB, Eilertsen D-E, Solem IKL, Arnevik EA, Korsnes MS, Ulstein ID. Effect of self-efficacy on quality of life in people with mild cognitive impairment and mild dementia: the mediating roles of depression and anxiety. Am J Alzheimers Dis Other Demen. 2020 Jan-Dec;35:1533317519885264. https://doi.org/10.1177/1533317519885264
  • 26 Peters M, Potter CM, Kelly L, Fitzpatrick R. Self-efficacy and health-related quality of life: a cross-sectional study of primary care patients with multi-morbidity. Health Qual Life Outcomes. 2019 Feb 14;17(1):37. https://doi.org/10.1186/s12955-019-1103-3
  • 27 Martinez-Martin P, Kurtis MM. Health-related quality of life as an outcome variable in Parkinson’s disease. Ther Adv Neurol Disord. 2012 Mar;5(2):105-17. https://doi.org/10.1177/1756285611431974
  • 28 Chenoweth L, Gallagher R, Sheriff JN, Donoghue J, Stein-Parbury J. Factors supporting self-management in Parkinson's disease: implications for nursing practice. Int J Older People Nurs. 2008 Sep;3(3):187-93. https://doi.org/10.1111/j.1748-3743.2008.00123.x
  • 29 Craig A, Wijesuriya N, Tran Y. The influence of self-efficacy on mood states in people with Spinal Cord Injury. ISRN Rehabilitation. 2013;2013:232978. https://doi.org/10.1155/2013/232978
  • 30 Ahmad ZR, Yasien S, Ahmad R. Relationship between perceived social self-efficacy and depression in adolescents. Iran J Psychiatry Behav Sci. 2014;8(3):65-74.
  • 31 Parada P, Oliva M, Lázaro E, Amayra I, Paz JFL, Martínez O, et al. Anxiety, depression and self-efficacy in patients with Myasthenia Gravis. Int J Psychol Psychol Ther. 2014;14(1):105-13.
  • 32 Tak YR, Brunwasser SM, Lichtwarck-Aschoff A, Engels RCME. The prospective associations between self-efficacy and depressive symptoms from early to middle adolescence: a cross-lagged model. J Yoth Adolesc. 2017 Apr;46(4):744-56. https://doi.org/10.1007/s10964-016-0614-z
  • 33 Hammen CL. Stress generation in depression: reflections on origins, research, and future directions. J Clin Psychol. 2006 Sep;62(9):1065-82. https://doi.org/10.1002/jclp.20293
  • 34 Bandura A. On the functional properties of perceived self-efficacy revisited. J Managet. 2012 Jan 1;38(1):9-44. https://doi.org/10.1177/0149206311410606